Astellas Pharma Inc

Common Name
Astellas Pharma
Country
Japan
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
13,643
Ticker
4503
Exchange
TOKYO STOCK EXCHANGE
Description
Astellas Pharma Inc. is a prominent pharmaceutical company that engages in the research, development, manufacture, and marketing of pharmaceutical products across the globe. Headquartered in Japan, th...

Astellas Pharma's Financial Statements Preview

Below are the financial statements of Astellas Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in trillions of JPY
2023 as of Not Specified
2022 as of Not Specified
2021 as of Not Specified
2020 as of Not Specified
2019 as of Not Specified
2018 as of Not Specified
Total assets
3.57a
2.46a
2.33a
2.27a
2.32a
1.9a
Total non-current assets
2.37a
1.41a
1.41a
1.4a
1.45a
1.04a
Total current assets
1.19a
1.05a
0.92a
0.87a
0.87a
0.86a
Total equity attributable to owners of the parent
1.6a
1.51a
1.46a
1.39a
1.29a
1.26a
Total non-current liabilities
0.69a
0.22a
0.18a
0.3a
0.23a
0.14a
Total current liabilities
1.29a
0.73a
0.69a
0.59a
0.8a
0.5a
Download Data

Verified Sources Behind Astellas Pharma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Astellas Pharma’s data sources below and access millions more through our Disclosure Search.

a. Astellas Pharma's Integrated Report 2024
a. Astellas Pharma's Integrated Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?